Hubei Jumpcan Pharmaceutical Co., Ltd. — Investor Relations & Filings
About Hubei Jumpcan Pharmaceutical Co., Ltd.
Hubei Jumpcan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of pharmaceutical products. The company maintains a diverse portfolio across therapeutic areas including pediatrics, digestive health, and respiratory care. It integrates traditional Chinese medicine with modern pharmaceutical science to produce a range of prescription and over-the-counter medications. Notable products include Pudilan Xiaoyan Oral Liquid, utilized for anti-inflammatory treatments, and Xiao'er Chixiao Tuishi Syrup, specifically formulated for pediatric use. The company operates advanced production facilities and emphasizes innovation in drug delivery systems and formulation technology. Its business model encompasses the entire value chain from raw material sourcing to clinical marketing, aiming to provide comprehensive health management solutions through a combination of traditional and chemical therapeutic options.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 国浩律师（上海）事务所关于湖北济川药业股份有限公司2022年限制性股票与股票期权激励计划注销部分股票期权并回购注销部分限制性股票之法律意见书 | 2026-04-23 | Chinese | |
| 湖北济川药业股份有限公司关于全资子公司利用闲置募集资金进行现金管理的公告 | 2026-04-23 | Chinese | |
| 独立董事候选人声明与承诺（侯艳莲） | 2026-04-23 | Chinese | |
| 湖北济川药业股份有限公司关于回购注销员工持股计划部分股份的公告 | 2026-04-23 | Chinese | |
| 湖北济川药业股份有限公司关于续聘会计师事务所的公告 | 2026-04-23 | Chinese | |
| 湖北济川药业股份有限公司董事会关于独立董事独立性自查情况的专项报告 | 2026-04-23 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 41159394 | 国浩律师（上海）事务所关于湖北济川药业股份有限公司2022年限制性股票与股票期权激励计划注销部分股票期权并回购注销部分限制性股票之法律意见书 | 2026-04-23 | Chinese | ||
| 41159390 | 湖北济川药业股份有限公司关于全资子公司利用闲置募集资金进行现金管理的公告 | 2026-04-23 | Chinese | ||
| 41159387 | 独立董事候选人声明与承诺（侯艳莲） | 2026-04-23 | Chinese | ||
| 41159384 | 湖北济川药业股份有限公司关于回购注销员工持股计划部分股份的公告 | 2026-04-23 | Chinese | ||
| 41159381 | 湖北济川药业股份有限公司关于续聘会计师事务所的公告 | 2026-04-23 | Chinese | ||
| 41159378 | 湖北济川药业股份有限公司董事会关于独立董事独立性自查情况的专项报告 | 2026-04-23 | Chinese | ||
| 41159368 | 湖北济川药业股份有限公司2025年度财务决算报告 | 2026-04-23 | Chinese | ||
| 41159360 | 湖北济川药业股份有限公司内部控制审计报告（2025年度） | 2026-04-23 | Chinese | ||
| 41159328 | 湖北济川药业股份有限公司关于变更注册资本并修订《公司章程》的公告 | 2026-04-23 | Chinese | ||
| 41159320 | 湖北济川药业股份有限公司关于回购注销部分限制性股票暨减少注册资本通知债权人的公告 | 2026-04-23 | Chinese | ||
| 41159312 | 华泰联合证券有限责任公司关于湖北济川药业股份有限公司调整部分募投项目子项目的核查意见 | 2026-04-23 | Chinese | ||
| 41159305 | 湖北济川药业股份有限公司2025年度独立董事述职报告（卢超军） | 2026-04-23 | Chinese | ||
| 41159297 | 湖北济川药业股份有限公司2026年员工持股计划（草案） | 2026-04-23 | Chinese | ||
| 41159289 | 湖北济川药业股份有限公司第十届董事会提名委员会关于第十一届董事会董事候选人任职资格的审查意见 | 2026-04-23 | Chinese | ||
| 41159287 | 湖北济川药业股份有限公司未来三年（2026年-2028年）股东回报规划 | 2026-04-23 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Hubei Jumpcan Pharmaceutical Co., Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/56821/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=56821 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=56821 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=56821 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 56821}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Hubei Jumpcan Pharmaceutical Co., Ltd. (id: 56821)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.